# Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

> **NCT03185793** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 198 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** SHR4640
- **DRUG:** benzbromarone

## Key facts

- **NCT ID:** NCT03185793
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-20
- **Primary completion:** 2018-07-20
- **Final completion:** 2018-07-20
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03185793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03185793, "Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03185793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*